Related Experiment Video
Updated: Jun 17, 2025
05:59
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
2.3K
Relationship Between Melatonin Receptor Agonists and Parkinson's Disease
Yoshihiro Noguchi1, Rikuto Masuda1, Haruka Aizawa1
1Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Journal of Pineal Research
|August 9, 2024
Summary
Ramelteon and tasimelteon show a negative association with Parkinson's disease risk. Agomelatine, however, shows a positive correlation, suggesting differential effects of melatonin receptor agonists on Parkinson's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Public Health
Background:
- Parkinson's disease (PD) affects millions globally, with projected increases in incidence and prevalence.
- Novel therapeutic strategies targeting sleep and circadian rhythms are under investigation for PD.
- Melatonin receptor agonists represent a potential class of drugs influencing these systems.
Purpose of the Study:
- To investigate the association between specific melatonin receptor agonists and Parkinson's disease.
- To evaluate the safety and potential differential effects of ramelteon, tasimelteon, and agomelatine in relation to PD.
Main Methods:
- Utilized the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) database.
- Defined Parkinson's disease cases using Standardized MedDRA Queries (SMQ) with narrow and broad preferred terms.
- Calculated the Reporting Odds Ratio (ROR) to assess the association between drug exposure and PD diagnosis.
Main Results:
- Ramelteon demonstrated a negative correlation with Parkinson's disease (ROR: 0.66, 95% CI: 0.51-0.84).
- Tasimelteon also showed a negative correlation with Parkinson's disease (ROR: 0.49, 95% CI: 0.38-0.62).
- Agomelatine exhibited a positive correlation with Parkinson's disease (ROR: 2.63, 95% CI: 2.04-3.40).
Conclusions:
- Ramelteon and tasimelteon appear to have a protective association with Parkinson's disease.
- Agomelatine may be associated with an increased risk of Parkinson's disease.
- Findings highlight the need for further research into melatonin receptor agonists for PD treatment, considering drug-specific effects and reporting system limitations.
Related Concept Videos
01:24Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
01:19Management of Insomnia
237
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
237
01:15Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
163
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
163
01:25Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K